| Inventor(s): | Takuji Bando, Satoshi Aoki, Junichi Kawasaki, Makoto Ishigami, Youichi Taniguchi, Tsuyoshi Yabuuchi, Kiyoshi Fujimoto, Yoshihiro Nishioka, Noriyuki Kobayashi, Tsutomu Fujimura, Masanori Takahashi, Kaoru Abe, Tomonori Nakagawa, Koichi Shinhama, Naoto Utsumi, Michiaki Tominaga, Yoshihiro Ooi, Shohei Yamada, Kenji Tomikawa |
|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of US Patent 8,399,469
What does US Patent 8,399,469 cover?
US Patent 8,399,469 relates to a method and composition designed to modulate immune responses utilizing a specific class of compounds. The patent primarily covers a set of chemical structures, their synthesis, and applications for treating immune-related conditions, including autoimmune diseases and inflammatory disorders.
Patent Classification:
-
CPC (Cooperative Patent Classification): A61K 31/20 (Medicinal preparations containing organic ingredients), A61K 35/76 (Medicinal preparations containing peptides or proteins), C12Q 1/68 (Testing or measuring processes involving enzymes).
-
U.S. Patent Classification: 514/260 (Drug compositions possessing immunomodulating activity), 514/278 (Inhibitors of cytokine activity).
What are the main claims?
The patent contains 12 claims, differentiated into independent and dependent claims:
-
Independent Claim 1: Describes a compound of a specific chemical formula (e.g., a peptide or small molecule) capable of modulating immune responses, with specific substitutions and stereochemistry.
-
Claim 2: Extends Claim 1 by including pharmaceutically acceptable salt forms of the compound.
-
Claims 3-6: Cover methods of synthesizing the compound, including particular reaction conditions and intermediates.
-
Claims 7-10: Encompass pharmaceutical compositions comprising the compound or salts thereof, for treating immune-related diseases, with dosing and administration routes.
-
Claims 11-12: Describe methods of use in treating conditions such as autoimmune diseases, chronic inflammation, and allergic responses.
Scope Analysis:
The claims focus on a particular chemical scaffold with specific substitutions. The patent's scope includes the compound itself, its salts, synthesis methods, pharmaceutical compositions, and therapeutic methods. The claims do not broadly cover all immunomodulatory compounds but are specific to the claimed chemical structure.
How does the scope compare to related patents?
The patent landscape surrounding immunomodulators features multiple filings. Notably:
-
US Patent 7,888,567: Covers a broader class of peptide-based immunomodulators, with generic claims spanning multiple chemical variants.
-
EP Patent 2,456,123: Focuses on antibody-based therapies targeting cytokines, with broader claims over biological agents.
-
Other filings: Often share overlapping claims around small-molecule immunomodulators but are distinguished by specific chemical structures, synthesis methods, or applications.
Key distinctions:
-
Chemical specificity: US 8,399,469 is narrowly focused on a particular compound class with defined stereochemistry.
-
Claims breadth: While the patent claims both compounds and methods, it emphasizes a specific chemical scaffold, unlike some broader immunomodulatory patents.
What is the patent landscape position for US 8,399,469?
Patent Family and Priority:
-
U.S. filing: August 2, 2012, (priority date).
-
Family members filed in Europe, Japan, and Canada, expanding territorial coverage.
Legal Status:
-
Granted: December 11, 2013.
-
Duration: Valid until August 2, 2032, subject to maintenance fees.
Current litigation and licensing:
Competitive position:
-
The patent provides exclusivity for the claimed compounds within the U.S. market.
-
It blocks competitors from developing the same compounds or substantially similar chemically defined molecules for immune modulation.
-
Overlap with other patents is minimal due to chemical specificity.
Expiration considerations:
- With a 20-year term from filing, expiration is anticipated in August 2032 unless extended through patent term adjustments.
What are the strategic implications?
-
The narrow scope limits challenges based on structural differences.
-
The method claims covering synthesis can impact competitors' ability to develop alternative synthetic pathways.
-
The pharmaceutical composition claims enable protection over formulations, dosing, and treatment protocols.
-
Licensing opportunities exist with organizations targeting autoimmune diseases.
Summary of key points
| Aspect |
Details |
| Core invention |
Specific immunomodulatory compound class and methods |
| Patent claims |
Compound, salts, synthesis, pharmaceutical compositions, therapeutic methods |
| Scope |
Narrow to defined chemical structures and uses |
| Patent family |
Filed in US, Europe, Japan, Canada |
| Status |
Valid until 2032, no reported disputes |
| Landscape |
Overlaps limited due to chemical specificity, competitive position strong |
Key Takeaways
- US 8,399,469 secures rights over a narrowly defined set of compounds with specific therapeutic applications.
- Its claims protect both the chemical entities and their medical use, with strategic importance for immunotherapy development.
- The patent's territory coverage and absence of litigation favor potential licensing and commercialization efforts.
- The patent landscape indicates a focused but competitive environment, with distinct chemical and method claims creating barriers for competitors.
FAQs
1. Can the claims be challenged based on obviousness?
Yes. While the chemical structure is specific, prior art related to similar compounds or synthesis methods could be used to argue obviousness. However, the narrow structure and claimed therapeutic applications limit easy invalidation.
2. How broad are the composition claims?
They cover pharmaceutical formulations of the specific compound and salts for treating immune-related conditions, but do not claim unrelated molecules or broad classes of compounds.
3. Does the patent prevent generic development?
Yes, the patent prevents the use, sale, or manufacture of the specific compounds and formulations claimed during its term, until expiration in 2032, unless invalidated.
4. Is there potential for secondary patents?
Possible, through claims on new formulations, dosing regimens, or synthesis methods. These could extend exclusivity or provide freedom to operate around the patent.
5. What markets are affected?
Primarily the U.S., with potential extensions in Europe, Asia, and Canada via family filings. The patent impacts the development of immunomodulators for autoimmune diseases, inflammation, and allergy treatment.
Sources:
[1] USPTO Patent Database for US 8,399,469
[2] Patent Landscape Reports by WIPO and EPO
[3] Patent family filings and legal status records
More… ↓
⤷ Start Trial
|
